Preclinical efficacy assessment of CDK4/6 inhibitory drugs in aggressive thyroid cancers and evaluation of phosphorylated CDK4 as sensitivity biomarker.
Steunen van het onderzoeksproject 'Preclinical efficacy assessment of CDK4/6 inhibitory drugs in aggressive thyroid cancers and evaluation of phosphorylated CDK4 as sensitivity biomarker'.
Ondersteuning
€ 90.000
Blijf op de hoogte van nieuwe ondersteunde individuen of organisaties
